This company listing is no longer active
Infinity Pharmaceuticals (INFI.Q) Stock Overview
Infinity Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, focuses on developing novel medicines for people with cancer. More details
| Snowflake Score | |
|---|---|
| Valuation | 2/6 |
| Future Growth | 0/6 |
| Past Performance | 0/6 |
| Financial Health | 0/6 |
| Dividends | 0/6 |
INFI.Q Community Fair Values
Create NarrativeSee what others think this stock is worth. Follow their fair value or set your own to get alerts.
Join community and earn perks
Infinity Pharmaceuticals, Inc. Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | US$0.000001 |
| 52 Week High | US$0.26 |
| 52 Week Low | US$0.000001 |
| Beta | 1.33 |
| 1 Month Change | -99.00% |
| 3 Month Change | -99.96% |
| 1 Year Change | -100.00% |
| 3 Year Change | -100.00% |
| 5 Year Change | -100.00% |
| Change since IPO | -100.00% |
Recent News & Updates
Recent updates
Shareholder Returns
| INFI.Q | US Biotechs | US Market | |
|---|---|---|---|
| 7D | 0% | 2.3% | 0.8% |
| 1Y | -100.0% | 42.3% | 20.2% |
Return vs Industry: INFI.Q underperformed the US Biotechs industry which returned 16% over the past year.
Return vs Market: INFI.Q underperformed the US Market which returned 31% over the past year.
Price Volatility
| INFI.Q volatility | |
|---|---|
| INFI.Q Average Weekly Movement | 188.6% |
| Biotechs Industry Average Movement | 10.3% |
| Market Average Movement | 7.3% |
| 10% most volatile stocks in US Market | 16.7% |
| 10% least volatile stocks in US Market | 3.2% |
Stable Share Price: INFI.Q's share price has been volatile over the past 3 months.
Volatility Over Time: INFI.Q's weekly volatility has increased from 89% to 189% over the past year.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 1995 | 30 | Seth Tasker | www.infi.com |
Infinity Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, focuses on developing novel medicines for people with cancer. The company’s product candidate, including eganelisib (IPI-549), an orally administered clinical-stage immuno-oncology product candidate that inhibits the enzyme phosphoinositide-3-kinase-gamma, which is in Phase 2 clinical trials for the treatment of metastatic triple negative breast cancer and urothelial cancer; and Phase 1/1b clinical trials for the treatment of solid tumors. Infinity Pharmaceuticals, Inc. has strategic alliances with Intellikine, Inc. to discover, develop, and commercialize pharmaceutical products targeting the delta and/or gamma isoforms of PI3K; Verastem, Inc. to research, develop, commercialize, and manufacture duvelisib and products containing duvelisib; and PellePharm, Inc. to develop and commercialize rights to its hedgehog inhibitor program, IPI-926, a clinical-stage product candidate, as well as collaboration agreements with F. Hoffmann-La Roche Ltd., and Bristol Myers Squibb Company. Infinity Pharmaceuticals, Inc. was founded in 1995 and is headquartered in Cambridge, Massachusetts.
Infinity Pharmaceuticals, Inc. Fundamentals Summary
| INFI.Q fundamental statistics | |
|---|---|
| Market cap | US$90.00 |
| Earnings (TTM) | -US$40.95m |
| Revenue (TTM) | US$2.57m |
Is INFI.Q overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| INFI.Q income statement (TTM) | |
|---|---|
| Revenue | US$2.57m |
| Cost of Revenue | US$28.53m |
| Gross Profit | -US$25.96m |
| Other Expenses | US$14.99m |
| Earnings | -US$40.95m |
Last Reported Earnings
Jun 30, 2023
Next Earnings Date
n/a
| Earnings per share (EPS) | -0.45 |
| Gross Margin | -1,010.35% |
| Net Profit Margin | -1,593.93% |
| Debt/Equity Ratio | -127.9% |
How did INFI.Q perform over the long term?
See historical performance and comparisonCompany Analysis and Financial Data Status
| Data | Last Updated (UTC time) |
|---|---|
| Company Analysis | 2024/03/11 15:42 |
| End of Day Share Price | 2024/03/11 00:00 |
| Earnings | 2023/06/30 |
| Annual Earnings | 2022/12/31 |
Data Sources
The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.
| Package | Data | Timeframe | Example US Source * |
|---|---|---|---|
| Company Financials | 10 years |
| |
| Analyst Consensus Estimates | +3 years |
|
|
| Market Prices | 30 years |
| |
| Ownership | 10 years |
| |
| Management | 10 years |
| |
| Key Developments | 10 years |
|
* Example for US securities, for non-US equivalent regulatory forms and sources are used.
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more.
Analysis Model and Snowflake
Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.
Learn about the world class team who designed and built the Simply Wall St analysis model.
Industry and Sector Metrics
Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on Github.
Analyst Sources
Infinity Pharmaceuticals, Inc. is covered by 23 analysts. of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.
| Analyst | Institution |
|---|---|
| Christopher Raymond | Baird |
| Andrew D'Silva | B. Riley Securities, Inc. |
| Michael King | Citizens JMP Securities, LLC |